Hsp90 chaperones are a significant target for cancer drug development. Here the authors find that some Hsp90 inhibitors are compatible with a partially closed conformation of Grp94 that can accept the client protein from BiP, while others prevent this conformational change and destabilize the BiP-Grp94-client complex.
- Tara P. Azam
- Jiaqi Han
- Timothy O. Street
